Clinical trials for cancer drugs were disrupted by the COVID-19 pandemic beginning in late March, according to a survey conducted by the market research firm IQVIA and the Cancer Research Institute (CRI) and published in Nature Reviews Drug Discovery on 18 May.
"Although the data are limited by the sample size, they indicate that patient enrollment in active clinical trials for cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?